Search Result

Results for "

muscular diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (3) Autophagy (1) Cathepsin (1) DNA/RNA Synthesis (1) Dynamin (1) ERK (1) Ferroptosis (1) HSP (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Liposome (1) Mitochondrial Metabolism (1) Mitophagy (1) Myosin (1) NAMPT (1) PPAR (2) Prostaglandin Receptor (3) Reactive Oxygen Species (ROS) (1) Reference Standards (1) REV-ERB (1) TGF-beta/Smad (1)
By Research Areas:	Cardiovascular Disease (3) Inflammation/Immunology (5) Metabolic Disease (9) Neurological Disease (10)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Cationic Lipids (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14415

SR8278 10+ Cited Publications	REV-ERB	Neurological Disease Metabolic Disease
SR8278 is a REV-ERBα antagonist and inhibits the REV-ERBα transcriptional repression activity with an EC₅₀ of 0.47 μM. SR8278 is used to regulate the metabolism in organisms and study biological rhythm. SR8278 also can be used for the research of Duchenne muscular dystrophy and Alzheimer's disease .

HY-P99441

Apitegromab SRK-015	TGF-beta/Smad	Neurological Disease
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .

HY-148799

Sevasemten EDG-5506	Myosin	Others
Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models .

HY-147332

TCL053	Liposome	Neurological Disease
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .

HY-125222

Drp1-IN-1	Dynamin	Others
Drp1-IN-1 is a dynamin-1-like protein (Drp1) inhibitor with an IC₅₀ of 0.91 μM. Drp1 mediates the fission of the outer mitochondrial membrane. Drp1-IN-1 can be used to study diseases associated with mitochondrial dysfunction .

HY-16361A

Omigapil maleate CGP3466B; CGP3446 maleate; TCH346 maleate	Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology
Omigapil maleate (CGP3466B), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ_1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD). Omigapil maleate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-149127

Rosolutamide ASC-JM17; ALZ-003	Keap1-Nrf2 Androgen Receptor HSP Mitophagy Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy	Metabolic Disease
Rosolutamide (ASC-JM17) is an orally active Nrf1/Nrf2 activator. Rosolutamide activates Hsf1 pathways, upregulates proteasome subunits and antioxidant enzymes, induces proteasome complex structural rearrangement, and enhances ubiquitin-proteasome system-mediated degradation. Rosolutamide reduces mutant androgen receptor and ataxin-3 aggregates, restores mitochondrial function, attenuates reactive oxygen species (ROS) levels, induces apoptosis and ferroptosis, and inhibits cancer cell growth. Rosolutamide can be used for the research of spinal and bulbar muscular atrophy, Huntington’s disease, and temozolomide-resistant glioblastoma .

HY-134377

Bocidelpar ASP0367; MA-0211	PPAR	Metabolic Disease
Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) .

HY-122604

PF-DcpSi	DNA/RNA Synthesis	Neurological Disease
PF-DcpSi is a mRNA decapping scavenger enzyme (DcpS) inhibitor (IC₅₀: 0.11 nM). PF-DcpSi (30 mg/kg,i.p.) ameliorates the disease phenotype in a mice model of spinal muscular atrophy (SMA) .

HY-109134

Pizuglanstat TAS-205 free base	Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Pizuglanstat (Compound 3; TAS-205 free base) is an orally active prostaglandin D synthase inhibitor with an IC₅₀ of 76 nM for human hematopoietic prostaglandin D synthase. Pizuglanstat inhibits the synthesis of PGD₂. Pizuglanstat improves experimental allergic rhinitis. Pizuglanstat can be used in the study of muscle regenerative diseases such as muscular dystrophy .

HY-147774

Cathepsin K inhibitor 6	Cathepsin	Others
Cathepsin K inhibitor 6 (compound 19) is an inhibitor of cathepsin K (Cat K) with an IC₅₀ of 17 nM. Cathepsin K inhibitor 6 also has inhibitory effects on other isoforms, with IC₅₀s of 0.05 μM (Cat L) and 0.3 μM (Cat B), respectively .

HY-163499

NAMPT activator-7	NAMPT	Cardiovascular Disease Neurological Disease
NAMPT activator-7 is a NAMPT activator with an EC₅₀ of <0.5 μM. NAMPT activator-7 can be used in research related to heart disease, Alzheimer's disease, Huntington's disease, Parkinson's disease and spinal cord injury .

HY-114898

ML404	Mitochondrial Metabolism	Cardiovascular Disease Neurological Disease
ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC₅₀=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke .

HY-107901

Pparδ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
Pparδ agonist 1 is a PPAR-δ agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

HY-109134A

Pizuglanstat hydrate TAS-205	Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Pizuglanstat hydrate (Compound 3; TAS-205) is an orally active prostaglandin D synthase inhibitor with an IC₅₀ of 76 nM for human hematopoietic prostaglandin D synthase. Pizuglanstat hydrate inhibits the synthesis of PGD₂. Pizuglanstat hydrate improves experimental allergic rhinitis. Pizuglanstat hydrate can be used in the study of muscle regenerative diseases such as muscular dystrophy .

HY-119460

Cuspin-1	ERK	Neurological Disease
Cuspin-1 is a upregulator of Survival of Motor Neuron protein (SMN). Cuspin-1 upregulates SMN expression post-transcriptionally, and increases the phosphorylation of Erk. Cuspin-1 can be used for research of neurodegenerative disease, such as spinal muscular atrophy (SMA) .

HY-16361

Omigapil CGP3466B free base; TCH346	Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology
Omigapil (CGP3466B free base), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ_1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil has the potential for the research of Alzheimer's disease. Omigapil is a apoptosis inhibitor. Omigapil can be used for the research of congenital muscular dystrophy (CMD). Omigapil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-B1139S

Tolperisone-d10 hydrochloride	Isotope-Labeled Compounds	Neurological Disease
Tolperisone-d₁₀ (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

HY-109134R

Pizuglanstat (Standard) TAS-205 free base (Standard)	Reference Standards Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Pizuglanstat (Standard) is the analytical standard of Pizuglanstat (HY-109134). This product is intended for research and analytical applications. Pizuglanstat (Compound 3; TAS-205 free base) is an orally active prostaglandin D synthase inhibitor with an IC₅₀ of 76 nM for human hematopoietic prostaglandin D synthase. Pizuglanstat inhibits the synthesis of PGD2. Pizuglanstat improves experimental allergic rhinitis. Pizuglanstat can be used in the study of muscle regenerative diseases such as muscular dystrophy .

Cat. No.	Product Name

HY-L086

Neurodegenerative Disease-related Compound Library	3,605 compounds
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour. MCE offers a unique collection of 3,605 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Neurodegenerative Disease-related Compound Library

3,605 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 3,605 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

TCL053	Biochemical Assay Reagents
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99441

Apitegromab SRK-015	TGF-beta/Smad	Neurological Disease
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .

Cat. No.	Product Name	Chemical Structure

HY-B1139S

Tolperisone-d10 hydrochloride
Tolperisone-d₁₀ (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

Tolperisone-d10 hydrochloride

Tolperisone-d₁₀ (hydrochloride) is the deuterium labeled Tolperisone hydrochloride. Tolperisone hydrochloride is a centrally acting muscle relaxant, is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

Cat. No.	Product Name		Classification

HY-16361A

Omigapil maleate CGP3466B; CGP3446 maleate; TCH346 maleate		Alkynes
Omigapil maleate (CGP3466B), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ_1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD). Omigapil maleate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-16361

Omigapil CGP3466B free base; TCH346		Alkynes
Omigapil (CGP3466B free base), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ_1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil has the potential for the research of Alzheimer's disease. Omigapil is a apoptosis inhibitor. Omigapil can be used for the research of congenital muscular dystrophy (CMD). Omigapil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

Cat. No.	Product Name		Classification

HY-147332

TCL053		Cationic Lipids
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.